| Referências: |
Artigos científicos 1. Willians et al. (1982) Cytoplasmatic inclusion bodies
in E. coli producing biosynthetic human insulin proteins. Science 215 687-689
2. Ouyang J et al. (2003) High-level expression, purification, and
characterization of porcine somatotropin in Pichia pastoris. Prot Expr Purif
32:28-34.3. Gasmi et al. (2007) AAV2-mediated delivery of human neurturin
to the rat nigrostriatal system: Long-term efficacy and tolerability of CERE120 for Parkinson's disease Neurobiol Dis 27: 67-76. 4. Zhang et al. (2003)
(2003Intravenous nonviral gene therapy causes normalization of striatal
tyrosine hydroxylase and reversal of motor impairment in experimental
parkinsonism. Hum. Gene Ther. 14:1-12 5. Xia et al. (2008) Intravenous glialderived neurotrophic factor gene therapy of experimental Parkinson's disease
with Trojan horse liposomes and a tyrosine hydroxylase Promoter. J Gene Med
10: 306-315 6. Wang et al. (2008) Sustained intraspinal delivery of
neurotrophic factor encapsulated in biodegradable nanoparticles following
contusive spinal cord injury. Biomaterials 29:4546-4553 (2008).7. Kim et al.
(2008) Local and systemic delivery of VEGF siRNA using polyelectrolyte
complex micelles for1. effective treatment of cancer. J Control Release
129:107-116 8. Zhang et al. (2004) Intravenous RNA interference gene
therapy targeting the human epidermal growth factor receptor prolongs
survival in intracranial brain cancer. Clin. Cancer Res. 10:3667-3677 9. Shen
et al. (2006) Supression of ocular neovascularization with siRNA targeting
VEGF receptor 1. Gene Ther 13:225-234. "" Revisões 1. Jana & Deb.
Strategies for efficient production of heterologous proteins in E. coli. Appl
Microbiol Biotechnol 67:289-98 (2005) 2. Cereghino & Cregg. Heterologous
protein expression in the methylotrophic yeast Pichia pastoris. FEMS Microb
Rev 24:45-66(2000).3. Kwon & Schaffer. Designer gene delivery vectors: molecular engineering and evolution of adeno-associated viral vectors for
enhanced gene transfer. Pharm Res 25:489-499 (2008) 4. Peterson & Nutt.
Treatment of Parkinson's Diseases with trophic factors. Neurotherap 5:270-
280 (2008). 5. Couvreur & Vauthier. Nanotechnology: intelligent design to
treat complex disease. Pharm Res 23:1417-1450 (2006) 6. Boado. Bloodbrain barrier transport of non-viral gene and RNAi therapeutics. Pharm Res
24:1772-1787 (2007) 7. Bergen et al. Nonviral approaches for neuronal
delivery of nucleic acids. Pharm Res 25_983-998 (2008).8. Kim & Rossi.
Strategies for silencing human disease using RNA interference. Nat Rev Gen
8: 173 - 184 (2007) 9. Gonzalez-Alegre. Therapeutic RNA interference for
neurodegenerative diseases: From promise to progress. Pharm. Therap.
114:34-55 (2007)."" Livros-texto1. Alberts et al. Essential Cell Biology. 3. Ed.
Garland Sc., Taylor and Francis Group, UK, 2010.2. Lodish et al. Molecular cell
biology. 6. Ed., W. H. Freeman and Company, USA, 2008.3. Krebs et al. Lewin
´s Genes X. 10. Ed. Jones and Bartlett Publishers, USA, 2011. 4. Watson et
al. DNA recombinante - genes e genomas. 3. Ed. Artmed, Porto Alegre, 2009.
5. Junqueira & Carneiro. Biologia Celular e Molecular. 8. Ed. Guanabara
Koogan, Rio de Janeiro, 2005.6. Fitzgerald-Hayes, Reichsman. DNA and
Biotechnology. 3. Ed. Elsevier, USA, 2010.7. Glick et al. Molecular
Biotechnology - principles and applications of recombinant DNA. 4. Ed., ASM
Press, USA, 2010.8. Primrose et al. Principles of gene manipulation. 6. ed.,
Blackwell Science Ltd., USA, 2001. 9. Sambrook & Russel. Molecular Cloning -
a laboratory manual. 3. Ed. Cold Spring Harbor Lab. Press, 2001. 10. Azevedo
et al. Técnicas básicas de biologia molecular. Editora UnB, Brasília, Brasil,
2003."
|
